Description

BUY SDB-006 ONLINE

SDB-006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB-006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

SDB-006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB-006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

SDB006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

SDB006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

SDB006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

SDB006 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB006 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB006 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).

.               .